Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis (RMS) trials, revealing that deaths from ...
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results